Publicaciones en colaboración con investigadores/as de Maastricht University Medical Centre (22)

2023

  1. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 2, pp. 198-205

2022

  1. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

2021

  1. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  2. Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 4, pp. 573-584

  3. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

2020

  1. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial

    Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654

  2. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

    Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942

  3. Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"

    Journal of Clinical Endocrinology and Metabolism

  4. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  5. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling

    Biological Psychiatry, Vol. 87, Núm. 2, pp. 100-112

  6. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Bone, Vol. 130

2019

  1. Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita

    Human Mutation, Vol. 40, Núm. 12, pp. 2270-2285

  2. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Archives of Osteoporosis, Vol. 14, Núm. 1

2018

  1. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

    Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794

  2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

    The Lancet, Vol. 391, Núm. 10117, pp. 230-240

  3. Teriparatide vs risedronate for osteoporosis – Authors' reply

    The Lancet

2017

  1. Predictors of intramyocardial hemorrhage after reperfused ST-segment elevation myocardial infarction

    Journal of the American Heart Association, Vol. 6, Núm. 8

  2. Reflections on ethical issues in palliative care for patients with heart failure

    European Journal of Palliative Care, Vol. 24, Núm. 1, pp. 18-22

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

  2. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention

    Journal of the American College of Cardiology, Vol. 67, Núm. 23, pp. 2705-2715